Phase III Data Support Premium Pricing For Vanda’s Sleep Drug Tasimelteon
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vanda anticipates that if approved, its drug for the rare “non-24-hour” circadian rhythm disorder will command pricing in line with orphan disease treatments. Second Phase III trial has it on track for a mid-2013 submission.